Mandana Chitsazan

Mandana Chitsazan

Auto-generated profile, based on publicly available information

Mandana Chitsazan

Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2014 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
ZTZiae Totonchi
Ziae Totonchi
FBFarah Baazm
Farah Baazm
MCMitra Chitsazan
Mitra Chitsazan
SSSomayeh Seifi
Somayeh Seifi
MCMandana Chitsazan
Mandana Chitsazan
Predictors of Prolonged Mechanical Ventilation after Open Heart Surgery

14 January 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
MCMitra Chitsazan
Mitra Chitsazan
AAAhmad Amin
Ahmad Amin
MCMandana Chitsazan
Mandana Chitsazan
NZnaghmeh ziaei
naghmeh ziaei
PMParviz Amri Maleh
Parviz Amri Maleh
Stephan Von HaehlingStephan Von Haehling
Stephan Von Haehling
The impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on diastolic function is less known. We describe a 46‐year‐old man with a history of mild hypertension who presented to the emergency department with fever, cough, and myalgia for 2 days. The patient was tested positive for SARS‐CoV‐2. He was admitted and started on a combination of antiviral and antimicrobial therapy. He developed respiratory distress 2 days later, and O2 saturation declined. Blood tests showed an increased N‐terminal pro‐B type natriuretic peptide (NT‐proBNP) level, and echocardiography showed normal left ventricular ejection fraction and E/e′ ratio of 16. Computed tomography scan showed interstitial pulmonary oedema and prominent peripheral pulmonary vascular markings. Given these findings, heart failure with preserved ejection fraction (HFpEF) was considered. Low‐dose diuretic was started, and fluid administration was restricted, resulting in a decrease in NT‐proBNP level, clinical and haemodynamic stabilization, and improved oxygenation. This case highlights the occurrence of HFpEF in coronavirus disease 2019.

1 January 2016
Verified
Journal Article
Open access
SHSeyed Mohammad Reza Hashemian
Seyed Mohammad Reza Hashemian
HJHamidreza Jamaati
Hamidreza Jamaati
BBBehrooz Farzanegan Bidgoli
Behrooz Farzanegan Bidgoli
FFFarin Rashid Farrokhi
Farin Rashid Farrokhi
MMMajid Malekmohammad
Majid Malekmohammad
MCMandana Chitsazan
Mandana Chitsazan
Acute Kidney Injury (AKI) is an unsolved clinical problem in critical care patients with a high mortality rate, increasing incidence, and no definitive therapy. We studied the incidence, risk factors, and mortality associated with AKI in ICU patients. In a prospective study, patient demographics, reason for hospitalization, reason for ICU admission, Length of ICU stay, laboratory data, and Vital signs were recorded in prepared forms during the ICU stay. AKI was defined as an increase in serum creatinine (SCr) of ≥ 0.3mg/dl from the baseline. A total of 200 patients who were enrolled in our study; 134 (67%) did not develop AKI during their ICU stay while 66 (33%) developed AKI (SCr ≥ 0.3) according to the AKIN definition. Patients with AKI had higher APACHE II scores (12.3±5.6 vs. 6.9±3.6; P< 0.001), longer ICU stays (7.6±7.6 vs. 3.7±2.8 days respectively; P< 0.001), and higher mortality (19.7% vs. 0.7%; P< 0.001). The AKIN criteria are clinically valid and can be a good predictor of mortality and patient outcome in addition to APACHE II score in ICU patients.

31 March 2011 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
BBBehnood Bikdeli
Behnood Bikdeli
BSBabak Sharif-Kashani
Babak Sharif-Kashani
ECEhsan Chitsaz
Ehsan Chitsaz
BBBavand Bikdeli
Bavand Bikdeli
MCMandana Chitsazan
Mandana Chitsazan
MMMohammad-Reza Masjedi
Mohammad-Reza Masjedi
Deep vein thrombosis (DVT) is a major health problem. Despite the wealth of studies on its epidemiology, few have described the thrombus sidedness and particularly the association of thrombus sidedness with clinical presentation and subsequent complications. This article reviews current knowledge regarding this topic and in light of recent data from a large prospective study. This is the first report from the prospective National Research Institute of Tuberculosis and Lung Disease DVT registry. Patients with ultrasound-confirmed symptomatic DVT were enrolled, and thrombus sidedness was investigated in each case. Computed tomography pulmonary angiography was used to diagnose coexisting pulmonary embolism (PE) in DVT patients with suggestive symptoms. Embolic burden score was calculated for those with PE. From the total of 100 patients, 45 had left-sided DVT, 41 had right-sided DVT, and 14 had bilateral DVT. Presenting symptoms and comorbidities were comparable, except for cancer, which was more common in those with right-sided involvement (either right-sided or bilateral DVT; p = 0.004). Compared with those with left-sided DVT, PE happened more frequently in right-sided DVT patients. Right-sided DVT patients also had a higher rate of massive PE (p = 0.03) and a greater mean embolic burden (13.32 ± 1.63 versus 6.05 ± 1.06; p = 0.001). These findings support raised awareness for global reconsideration of the assumption of complete identicalness of right-sided and left-sided DVT. Although future studies are needed to better elucidate epidemiological and prognostic differences based on the thrombus sidedness, our preliminary findings suggest that the two are not completely identical and right-sided DVT might be more ominous.

16 December 2015 in Research in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SHShokoufeh Hajsadeghi
Shokoufeh Hajsadeghi
MCMandana Chitsazan
Mandana Chitsazan
MCMitra Chitsazan
Mitra Chitsazan
NSNegar Salehi
Negar Salehi
AAAhmad Amin
Ahmad Amin
MMMaryam Mohsenian
Maryam Mohsenian
Background: The crucial role of inflammation in the development and progression of atherosclerosis has been previously described. However, there is insufficient data available to demonstrate the changes in high sensitivity C-reactive protein (hs-CRP) during clopidogrel therapy. Objectives: In the present study, we aimed to assess the changes in the inflammatory marker of coronary heart disease, i.e., hs-CRP during clopidogrel therapy, in patients undergoing percutaneous coronary intervention (PCI). We also evaluated the anti-inflammatory effects of clopidogrel, if any, in different groups of patients. Patients and Methods: The study population included 650 consecutive patients who underwent elective, urgent, or emergent PCI. Patients received a 300-mg loading dose of clopidogrel (Plavix®) and aspirin either 24 hours before the planned PCI, or immediately before the procedure in patients with urgent or emergent PCI, followed by a 75-mg daily maintenance dose for up to 12 weeks. At the end of the 12th week, hs-CRP was re-assessed. Results: Six hundred-fifty patients including 386 (59.4%) male and 264 (40.6%) female subjects were enrolled in the study. The mean hs-CRP level was 15.36 ± 9.83 mg/L with a median of 14 mg/L (interquartile range 8 to 19.6 mg/L). Female, hypertensive, diabetic, and non-smoking patients had higher reductions in hs-CRP in response to clopidogrel therapy compared to male, non-hypertensive, non-diabetic and smoker patients, respectively (all P < 0.005). The changes in the hs-CRP levels were also statistically different in patients with various index events before PCI (P < 0.001). No significant differences were observed in the mean reduction of hs-CRP between the patients without stent implantation and those with bare metal or drug-eluting stents (P = 0.07), respectively. Conclusions: We found that the use of clopidogrel in patients undergoing PCI had favorable effects on the suppression of hs-CRP. This effect appears to be heightened and more apparent in some group of patients with co-morbidities such as diabetes and hypertension. Keywords: C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Percutaneous Coronary Intervention

1 January 2016 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
SHShokoufeh Hajsadeghi
Shokoufeh Hajsadeghi
MCMandana Chitsazan
Mandana Chitsazan
MCMitra Chitsazan
Mitra Chitsazan
NSNegar Salehi
Negar Salehi
AAAhmad Amin
Ahmad Amin
SMSamar Moghadami
Samar Moghadami
Objectives: A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP) in patients undergoing percutaneous coronary intervention (PCI). Methods: The present randomized, double-blind clinical trial included 120 patients who underwent PCI. Eligible patients were randomly assigned 2:1 to one of the two groups: 80 patients in the first group received clopidogrel (Plavix®; loading dose and maintenance dose of 300 and 75 mg daily, respectively) and 40 patients in the second group received prasugrel (Effient®; loading dose and maintenance dose of 60 and 10 mg, respectively) for 12 weeks. The hs-CRP levels between baseline and 12th week were compared. Results: Of the 120 patients, 69 patients (57.5%) were male. Pretreatment hs-CRP level was statistically comparable in clopidogrel (median, 15.10 mg/dL; interquartile range [IQR], 9.62-23.75 mg/dL) and prasugrel groups (median, 18 mg/dL; IQR, 14.25-22 mg/dL; P = 0.06). Patients taking clopidogrel showed a significant reduction in hs-CRP level compared with the baseline values ( P < 0.001). Prasugrel administration also resulted in a significant reduction in hs-CRP level ( P < 0.001). A significant 73% overall reduction in the hs-CRP level was seen with prasugrel compared with 39% overall reduction in hs-CRP level with clopidogrel ( P 0.002). Conclusion: Prasugrel seems to be superior to clopidogrel in the reduction of hs-CRP in patients undergoing PCI.